PHA Classroom: e-Learning. Anytime. Anyplace.

>> Back to Recordings
 
Session Recording from PHA's 2010 9th International PH Conference

PDE-5 Inhibitors: Sildenafil and Tadalafil

June 26, 2010 

This session will cover the phosphodiesterase inhibitors (PDE-5 inhibitors) and their role in the treatment of pulmonary arterial hypertension. The mechanism of action of these drugs will be briefly discussed, as well as their potential benefits and associated risks. The evidence supporting their use will be briefly presented.

View session handout (PDF)

The below recording will begin automatically. To view the controls, move your mouse anywhere over the video then move to the control interface at the bottom of the video.

 

 

Presenter Information

-David Badesch, MD, University of Colorado Denver, Denver, Colo., chair
-James Tarver, III, MD, Florida Hospital, Orlando, Fla.
-Joy Beckmann, RN, MSN, Harbor-UCLA Medical Center, Torrance, Calif.
-Ioana Preston, MD, Tufts University School of Medicine, Boston, Mass.

 

>>If you liked this recording, you may enjoy Inhaled/Oral Prostacyclins

Inhaled/Oral Prostacyclins panelists

DIAMOND
SUPPORTER

PLATINUM
SUPPORTER

GOLD
SUPPORTER

SILVER
SUPPORTER

Actelion Pharmaceuticals US, Inc. Gilead Sciences, Inc. United Therapeutics Corporation Bayer HealthCare
This is a program of the PHA Medical Education Fund, made possible through unrestricted educational grants from our supporters.

 

The information provided on the PHA website is provided for general information only. It is not intended as legal, medical or other professional advice, and should not be relied upon as a substitute for consultations with qualified professionals who are familiar with your individual needs.

© 2014 Pulmonary Hypertension Association. All Rights Reserved.

801 Roeder Road, Ste. 1000, Silver Spring, MD 20910   Patient-to-Patient Support Line: 1-800-748-7274
Webmaster@PHAssociation.org
    Privacy Policy   Virtual Tour of Website    Provide Feedback & Report Bugs

Designed by Matrix Group International, Inc.®

NORD

The National Organization for Rare Disorders (NORD) awarded PHA the Abbey S. Meyers Leadership Award in 2012 for outstanding service to PHA members in advocacy, education and other key areas.